2-(1-Hydroxybutan-2-yloxy)propyl 5-[2-(2,5-dioxopyrrol-1-yl)ethylamino]-5-oxopentanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-(1-Hydroxybutan-2-yloxy)propyl 5-[2-(2,5-dioxopyrrol-1-yl)ethylamino]-5-oxopentanoate
• 英文别名: 2-(1-hydroxybutan-2-yloxy)propyl 5-[2-(2,5-dioxopyrrol-1-yl)ethylamino]-5-oxopentanoate
• 化学式: C₁₈H₂₈N₂O₇
• 分子量: 384.4
• InChiKey: PWLBWIVWNOMMED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  27
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  122
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] AURISTATIN COMPOUNDS AND CONJUGATES THEREOF<br/>[FR] COMPOSÉS AURISTATINE ET LEURS CONJUGUÉS
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2014093379A1

  公开（公告）日：2014-06-19

  An auristatin compound conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD- D, the protein based recognition-molecule being connected to the polymeric carrier by Lp. Each occurrence of D is independently an auristatin compound having a molecular weight ≤ 5 kDa. LD and Lp are distinct linkers connecting the auristatin compound and PBRM to the polymeric earner respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-auristatin compound-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种auristatin化合物结合物。该结合物包括基于蛋白质的识别分子（PBRM）和聚合物载体，其被取代一个或多个-LD-D，其中，基于蛋白质的识别分子通过Lp与聚合物载体相连。每个D的出现都是独立的，具有分子量≤5 kDa的auristatin化合物。LD和Lp是连接auristatin化合物和PBRM到聚合物载体的不同连接物。还揭示了用于与PBRM结合形成聚合物-auristatin化合物-PBRM结合物的聚合物支架，以及包括结合物的组合物，其制备方法以及使用结合物或其组合物治疗各种疾病的方法。
• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：Mersana Therapeutics, Inc.

  公开号：EP2717916B1

  公开（公告）日：2017-03-08
• [EN] PROTEIN-POLYMER-DRUG CONJUGATES<br/>[FR] CONJUGUÉS PROTÉINE-POLYMÈRE-MÉDICAMENT
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2014093394A1

  公开（公告）日：2014-06-19

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by Lp. Each occurrence of D is independently a therapeutic agent having a molecular weight < 5 kDa. LD and Lp are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer- drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.